NASDAQ:FOLD Amicus Therapeutics (FOLD) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free FOLD Stock Alerts $11.78 -0.08 (-0.67%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$11.49▼$11.9350-Day Range$11.43▼$14.0052-Week Range$9.70▼$14.57Volume2.48 million shsAverage Volume3.27 million shsMarket Capitalization$3.48 billionP/E RatioN/ADividend YieldN/APrice Target$20.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Amicus Therapeutics alerts: Email Address Amicus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside69.8% Upside$20.00 Price TargetShort InterestBearish10.97% of Shares Sold ShortDividend StrengthN/ASustainability-1.28Upright™ Environmental ScoreNews Sentiment1.05Based on 9 Articles This WeekInsider TradingSelling Shares$3.28 M Sold Last QuarterProj. Earnings Growth1,650.00%From $0.02 to $0.35 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.18 out of 5 starsMedical Sector189th out of 938 stocksPharmaceutical Preparations Industry75th out of 417 stocks 3.5 Analyst's Opinion Consensus RatingAmicus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.00, Amicus Therapeutics has a forecasted upside of 69.8% from its current price of $11.78.Amount of Analyst CoverageAmicus Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted10.97% of the outstanding shares of Amicus Therapeutics have been sold short.Short Interest Ratio / Days to CoverAmicus Therapeutics has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.Change versus previous monthShort interest in Amicus Therapeutics has recently increased by 4.82%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAmicus Therapeutics does not currently pay a dividend.Dividend GrowthAmicus Therapeutics does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmicus Therapeutics has received a 63.50% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Fabry disease medication", "Clinical research services for genetic diseases", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Amicus Therapeutics is -1.28. Previous Next 3.4 News and Social Media Coverage News SentimentAmicus Therapeutics has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Amicus Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 13 people have searched for FOLD on MarketBeat in the last 30 days. This is a decrease of -24% compared to the previous 30 days.MarketBeat Follows5 people have added Amicus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amicus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,283,723.00 in company stock.Percentage Held by InsidersOnly 2.10% of the stock of Amicus Therapeutics is held by insiders. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Amicus Therapeutics are expected to grow by 1,650.00% in the coming year, from $0.02 to $0.35 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amicus Therapeutics is -23.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amicus Therapeutics is -23.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmicus Therapeutics has a P/B Ratio of 21.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… About Amicus Therapeutics Stock (NASDAQ:FOLD)Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late-onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.Read More FOLD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FOLD Stock News HeadlinesMarch 16, 2024 | insidertrades.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Director Sells $100,500.00 in StockMarch 23, 2024 | americanbankingnews.comQ1 2024 EPS Estimates for Amicus Therapeutics, Inc. (NASDAQ:FOLD) Boosted by Zacks ResearchMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!March 22, 2024 | americanbankingnews.comZacks Research Weighs in on Amicus Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:FOLD)March 21, 2024 | americanbankingnews.comTraders Buy Large Volume of Call Options on Amicus Therapeutics (NASDAQ:FOLD)March 20, 2024 | globenewswire.comAmicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) ReportMarch 19, 2024 | americanbankingnews.comAmicus Therapeutics (NASDAQ:FOLD) Price Target Cut to $19.00 by Analysts at JPMorgan Chase & Co.March 16, 2024 | ca.finance.yahoo.comFOLD Jul 2024 12.000 callMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!March 7, 2024 | finance.yahoo.comFOLD Oct 2024 12.000 callMarch 7, 2024 | finance.yahoo.comFOLD Jan 2025 12.000 putMarch 7, 2024 | finance.yahoo.comFOLD Jul 2024 9.000 putMarch 7, 2024 | finance.yahoo.comDirector Margaret Mcglynn Sells 15,000 Shares of Amicus Therapeutics Inc (FOLD)March 6, 2024 | finance.yahoo.comAmicus Therapeutics Stock Sees RS Rating Improve To 74March 2, 2024 | finance.yahoo.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?March 1, 2024 | seekingalpha.comAmicus Therapeutics, Inc. (FOLD) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Amicus (FOLD), Xenon (XENE) and Veeva Systems (VEEV)March 1, 2024 | markets.businessinsider.comBuy Rating Affirmed: Amicus’s Strong Product Launch and Growth TrajectoryMarch 1, 2024 | finance.yahoo.comAmicus Therapeutics Full Year 2023 Earnings: EPS Misses ExpectationsMarch 1, 2024 | globenewswire.comAmicus Therapeutics to Present at Upcoming Investor Conferences in March 2024February 29, 2024 | finance.yahoo.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | seekingalpha.comAmicus Therapeutics: Expect Improved Commercial Momentum In 2024February 29, 2024 | finance.yahoo.comQ4 2023 Amicus Therapeutics Inc Earnings CallFebruary 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for Amicus with Strong Growth and Promising OutlookFebruary 28, 2024 | finanznachrichten.deAmicus Therapeutics, Inc.: Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate UpdatesFebruary 28, 2024 | finance.yahoo.comAmicus Therapeutics Inc (FOLD) Reports 21% Revenue Growth in 2023, Eyes Non-GAAP Profitability ...February 28, 2024 | msn.comAmicus Therapeutics Non-GAAP EPS of $0.01 beats by $0.05, revenue of $115.08M in-lineSee More Headlines Receive FOLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today3/29/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:FOLD CUSIP03152W10 CIK1178879 Webwww.amicusrx.com Phone(215) 921-7600Fax609-662-2001Employees517Year Founded2002Price Target and Rating Average Stock Price Target$20.00 High Stock Price Target$22.00 Low Stock Price Target$19.00 Potential Upside/Downside+69.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.51) Trailing P/E RatioN/A Forward P/E Ratio589.00 P/E GrowthN/ANet Income$-151,580,000.00 Net Margins-37.96% Pretax Margin-37.59% Return on Equity-119.46% Return on Assets-20.40% Debt Debt-to-Equity Ratio2.42 Current Ratio2.88 Quick Ratio2.52 Sales & Book Value Annual Sales$399.36 million Price / Sales8.71 Cash FlowN/A Price / Cash FlowN/A Book Value$0.55 per share Price / Book21.42Miscellaneous Outstanding Shares295,380,000Free Float289,180,000Market Cap$3.48 billion OptionableOptionable Beta0.77 Social Links 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. John F. Crowley (Age 57)Executive Chairman Comp: $1.88MMr. Bradley L. Campbell M.B.A. (Age 48)CEO, President & Director Comp: $984.09kMs. Ellen S. Rosenberg (Age 61)Chief Legal Officer & Corporate Secretary Comp: $733.94kMr. David M. Clark (Age 49)Chief People Officer Comp: $701.39kDr. Jeffrey P. Castelli (Age 52)Chief Development Officer Comp: $709.64kMr. Simon Nicolas Reade Harford (Age 64)Chief Financial Officer Ms. Samantha Prout (Age 46)Chief Accounting Officer & Controller Dr. Jill Weimer Ph.D.Chief Science OfficerAndrew FaughnanSenior Director of Investor RelationsMr. Patrik S. Florencio Esq.Global Chief Compliance & Risk OfficerMore ExecutivesKey CompetitorsTurning Point TherapeuticsNASDAQ:TPTXAlkermesNASDAQ:ALKSMadrigal PharmaceuticalsNASDAQ:MDGLGeronNASDAQ:GERNDynavax TechnologiesNASDAQ:DVAXView All CompetitorsInsiders & InstitutionsHealthcare of Ontario Pension Plan Trust FundBought 43,000 shares on 3/21/2024Ownership: 0.108%Vanguard Group Inc.Bought 1,360,613 shares on 3/11/2024Ownership: 9.646%Wellington Management Group LLPBought 7,666,335 shares on 3/5/2024Ownership: 5.143%Margaret G McglynnSold 7,500 sharesTotal: $100,500.00 ($13.40/share)Goldman Sachs Group Inc.Sold 395,339 shares on 3/1/2024Ownership: 0.724%View All Insider TransactionsView All Institutional Transactions FOLD Stock Analysis - Frequently Asked Questions Should I buy or sell Amicus Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" FOLD shares. View FOLD analyst ratings or view top-rated stocks. What is Amicus Therapeutics' stock price target for 2024? 3 Wall Street research analysts have issued 1 year target prices for Amicus Therapeutics' shares. Their FOLD share price targets range from $19.00 to $22.00. On average, they predict the company's stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 69.8% from the stock's current price. View analysts price targets for FOLD or view top-rated stocks among Wall Street analysts. How have FOLD shares performed in 2024? Amicus Therapeutics' stock was trading at $14.19 at the start of the year. Since then, FOLD shares have decreased by 17.0% and is now trading at $11.78. View the best growth stocks for 2024 here. When is Amicus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our FOLD earnings forecast. How were Amicus Therapeutics' earnings last quarter? Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted its quarterly earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.06) by $0.05. The biopharmaceutical company earned $115.08 million during the quarter, compared to the consensus estimate of $115.11 million. Amicus Therapeutics had a negative trailing twelve-month return on equity of 119.46% and a negative net margin of 37.96%. What ETFs hold Amicus Therapeutics' stock? ETFs with the largest weight of Amicus Therapeutics (NASDAQ:FOLD) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), Global X Guru Index ETF (GURU), WisdomTree BioRevolution Fund (WDNA), SPDR S&P Biotech ETF (XBI), iShares U.S. Pharmaceuticals ETF (IHE) and Principal Healthcare Innovators ETF (BTEC). What guidance has Amicus Therapeutics issued on next quarter's earnings? Amicus Therapeutics updated its FY 2023 earnings guidance on Monday, January, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $399.4 million-$399.4 million, compared to the consensus revenue estimate of $396.5 million. What is John F. Crowley's approval rating as Amicus Therapeutics' CEO? 21 employees have rated Amicus Therapeutics Chief Executive Officer John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among the company's employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Amicus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX). Who are Amicus Therapeutics' major shareholders? Amicus Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.72%), Vanguard Group Inc. (9.65%), Perceptive Advisors LLC (9.57%), Wellington Management Group LLP (5.14%), Palo Alto Investors LP (3.54%) and Fiera Capital Corp (1.73%). Insiders that own company stock include Bradley L Campbell, Bradley L Campbell, Burke W Whitman, Burke W Whitman, Daphne Quimi, David Michael Clark, Ellen Rosenberg, Ellen Rosenberg, Jeff Castelli, John F Crowley, John F Crowley, Lynn Dorsey Bleil, Margaret G Mcglynn, Michael Raab and Samantha Prout. View institutional ownership trends. How do I buy shares of Amicus Therapeutics? Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FOLD) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.